Navigation Links
New Hope to Beat Cancer
Date:3/12/2009

Aurora St. Luke's is one of a few institutions in the world to offer skin cancer clinical trial.

MILWAUKEE, March 12 /PRNewswire/ -- Aurora St. Luke's Medical Center is one of the first institutions in the world to offer a new skin cancer research study that trains the patient's immune system to kill cancer cells.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090303/CG78204LOGO-b)

The Young Tumor-Infiltrating Lymphocyte (Y-TIL) trial is a phase 2 clinical trial being offered with technical support from the National Cancer Institute (NCI) in Bethesda, Md. Milwaukee native Jeff Capstran participated in an earlier stage of this trial at NCI. Capstran had stage-four metastatic melanoma, a diagnosis that few survive, but with small kids at home he was determined to find treatment options.

"I knew that my illness was very serious, but there had to be new opportunities to fight back," Capstran says. "When I found out about the study at NCI, I knew I had to jump at the chance. Today, I am cancer free."

The early results from a similar trial at the NCI are exciting for patients with stage-four metastatic melanoma. Published reports for the trial show a 51 percent response rate.

To qualify, all patients must be diagnosed with stage-four metastatic melanoma. During the trial blood is drawn from the patient, along with a sample of the tumor. The T cells, which are the immune system's killer cells, are extracted from the tumor and re-educated to attack the cancer cells. The patient's normal immune system is then temporarily suppressed using chemotherapy, and the newly trained T cells are returned to the patient. The T cells are expected to survive, replicate and kill the cancer.

The trial has a capacity for 75 patients over a three-year period. Of those 41 are expected to qualify for the entire process. With the success of this program, the next step is a phase 3 trial where hundreds of patients would be enrolled and treated.

Due to the experimental features of this clinical trial, some portions of the study may not be covered by health insurance. As a not-for-profit, Aurora Health Care's philanthropy program has secured more than $2 million in support from outside donors, including $50,000 from Anne's Hope Foundation.

Milwaukee's own Northwestern Mutual Foundation has made its largest health care donation of $750,000 to Aurora's immunotherapy program, which has oversight of the Y-TIL Trial. Other contributors include A. Elser, Jr., William Schuett, Sr., Stella Jones and Sherwood and Libby Temkin.

To keep the trial affordable for all who participate, an additional $700,000 in donations is being sought for each year of the program, a total of over $2,000,000.

Aurora Health Care is a not-for-profit Wisconsin health care provider and a national leader in efforts to improve the quality of care. Aurora provides care at sites in more than 90 communities throughout eastern Wisconsin and Illinois.

Online newsroom: www.Aurora.org/Newsroom

Clinical trial information: www.aurora.org/y-til


'/>"/>
SOURCE Aurora Health Care
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
(Date:6/23/2016)...  MedSource announced today that it has selected ... of choice.  This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
Breaking Medicine News(10 mins):